Market Newsdesk

WALTHAM, Mass., Feb. 17, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has acquired cell sorting technology assets from Propel Labs, a wholly-owned subsidiary of SIDIS Corp. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher’s Biosciences business. Propel Labs will continue to operate as a separate entity and serve its existing customers.

“Cell sorting is an essential discovery tool used by many of our customers, allowing for the separation of specific cell types from complex samples. A first-of-its kind, the Bigfoot Spectral Cell Sorter brings more powerful sorting capabilities, faster throughput and novel safety features complementing our already strong flow cytometry offering,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “As the market for cell and gene therapies, immuno-oncology and other promising medicines drive increased expectations from researchers, we are really well positioned to support our customers in their work to improve healthcare outcomes.”

Researchers are asking for cytometry analysis and sorting techniques with greater multiplexing capabilities to gain deeper biological insights. Current tools only meet some of these challenges. The high-speed electronics and innovative design of the Bigfoot Spectral Cell Sorter accelerate sorting by up to 10 times that of other available technologies, while maintaining cell viability and improving ease of use. It also has an integrated Class II biocontainment system that eliminates the need for separate biosafety cabinets. With this new technology, researchers can study more cell populations from samples of limited quantity, enabling a better understanding of biological systems at a scale and resolution needed for advancing science.

Stevenson added, “We look forward to welcoming the highly talented members of the Propel Labs Bigfoot team who bring additional flow cytometry expertise, R&D capabilities and engineering strength to Thermo Fisher, helping to further elevate our cell analysis and cell therapy research business.”  

The Biosciences business is part of the Life Sciences Solutions Segment. 

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

About SIDIS Corp.

SIDIS Corp. is a global, privately held, purpose-driven company that invests in and manages market-leading life science companies to advance human health. For more information, please visit www.sidisglobal.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward looking statements as representing our views as of any date subsequent to today.

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: [email protected]

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: [email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-acquires-leading-cell-sorting-technology-from-propel-labs-301229509.html

SOURCE Thermo Fisher Scientific

HOUSTON, Feb. 17, 2021 /PRNewswire/ — U.S. Well Services, Inc. (Nasdaq: USWS) today announced that a Nasdaq Hearings Panel (the “Panel”) has granted its request for an extension of time to demonstrate compliance with Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).  As a condition of the Panel’s decision, the Company is required to demonstrate compliance with the Minimum Bid Price Rule by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by June 7, 2021.  As of the close of business on February 16, 2021, the Company has demonstrated a closing bid price of at least $1.00 per share for seven consecutive trading days.

As previously announced, the Company received notice from Nasdaq on December 29, 2020, informing the Company that it had not regained compliance with the Minimum Bid Price Rule, that it was not eligible for an additional 180 calendar day extension period to regain compliance and that the Nasdaq’s staff had determined to delist the Company’s common stock from Nasdaq.  The Company appealed the staff’s determination to the Panel, at which it requested continued listing on Nasdaq subject to an exception to the Minimum Bid Price Rule. 

“We are pleased to receive the extension from the Panel that will enable U.S. Well Services to continue to be listed on the Nasdaq during the extension,” said Joel Broussard, the Company’s Chief Executive Officer.  “I believe we will be able to regain compliance with the Minimum Bid Price Rule during this extension period, which will allow us to maintain our listing status for our shareholders.”

About U.S. Well Services, Inc.

U.S. Well Services, Inc. is a leading provider of hydraulic fracturing services and a market leader in electric fracture stimulation. The Company’s patented electric frac technology provides one of the first fully electric, mobile well stimulation systems powered by locally-supplied natural gas, including field gas sourced directly from the wellhead. The Company’s electric frac technology dramatically decreases emissions and sound pollution while generating exceptional operational efficiencies, including significant customer fuel cost savings versus conventional diesel fleets. For more information visit: www.uswellservices.com. Information on our website is not part of this release.

Contacts:
U.S. Well Services
Josh Shapiro
Vice President, Finance and Investor Relations
[email protected] 

Dennard Lascar Investor Relations
(713) 529-6600
[email protected]

View original content:http://www.prnewswire.com/news-releases/us-well-services-receives-nasdaq-listing-extension-301229755.html

SOURCE U.S. Well Services, Inc.

THC.CSE
THCBF
 
– OTC
TFHD.F

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ – THC BioMed Intl Ltd. (“THC BioMed” or the “Company“) discloses that Fundamental Research Corp. has updated its independent investment analysis coverage on THC BioMed with a note and change of valuation.

Fundamental Research Corp. is an issuer-paid independent research house. THC BioMed notes this development for information only and does not endorse the contents of Fundamental Research Corp.’s report.

About
 
THC

THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed.  In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fundamental-research-corp-updates-investment-analysis-coverage-on-thc-biomed-301229761.html

SOURCE THC BioMed

MIAMI and TORONTO, Feb. 17, 2021 /PRNewswire/ – XTM, Inc. (“XTM” or the “Company”) (QB: XTMIF) (CSE: PAID), (FSE: 7XT), a Miami and Toronto-based Fintech company in the neo-banking space, providing mobile banking and payment solutions around the world, is pleased to announce it has signed a Letter of Intent (“LOI”) with Harlo Entertainment (“HARLO”), one of the largest hospitality and entertainment groups in North America.

Harlo Entertainment has in excess of $250M in assets under management with a focus on investments in the hospitality, entertainment, lifestyle, and technology industries.  As part of the terms of the LOI, XTM will work with Harlo to roll-out its hospitality-focused Today mobile app and payout solution to meet the requirements of  all of its Harlo Entertainment properties http://www.harloentertainment.com/investments/.

“We look forward to working with this innovative fintech company XTM, to provide our employees with instant access to their earnings with a free and elegant user experience,” commented Mike Kimel, Chairman and Co-Founder, Harlo Entertainment. “The hard-working employees of our companies are the life blood of our business. We are committed to empowering them with tools that create a fair work environment and financial inclusion for the benefit of all.”

“Harlo Entertainment represents top-shelf brands that we are thrilled to add to our growing customer base,” said Marilyn Schaffer, CEO. “This is a strategic partnership for a number of reasons; one that will grow into a significant opportunity for XTM.  We believe we can deliver tremendous value to the Harlo team and we are further committed to serving-up some quick wins that will provide value additions for all.”

About XTM Inc.

XTM, www.xtminc.com is a Miami and Toronto-based fintech innovator in the neo-banking space helping business and workers alike expedite earnings payout and eliminate banking fees. We are a global card issuer and real-time payment specialist providing our technology to businesses to automate and expedite worker payouts that can also eliminate cash. XTM integrates businesses to a payment ecosystem that is coupled with a free mobile app and a Visa or Mastercard debit card with free banking features. XTM drives enterprise value and creates a positive user experience.

About Harlo Entertainment

Harlo Entertainment is a North American investment group focused on the hospitality, entertainment, lifestyle, and technology industries.  We leverage our expertise; we actively support and focus on the growth of all our investments from the ground up.  We take a value-oriented approach to investing and have a clear focus on operational improvements to drive performance and growth. Notable ventures include co-founding Chase Hospitality Group (CHG), a globally recognized brand, responsible for creating leading culinary destinations, including their flagship award-winning restaurant, The Chase. As well as playing a key role in the development and success of Miami landmarks Komodo, Swan and Papi Steak. 

For further information
Email: [email protected]

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (the “forward-looking statements”), within the meaning of applicable Canadian securities legislation, including expected performance of XTM, the expectation that businesses with which XTM does business or have committed to do business will in the expected timeline, the continuing trend toward electronic payment methods, that the integrations will attract new business owners to use the Today program, and the general conditions and revenues of XTM.  Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur. While XTM can make best efforts to estimate when businesses will re-open or back to pre-Covid 19 business  levels there are no guarantees this will happen in the time the Company expects or if at all.  All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. These forward-looking statements are made as of the date of this news release. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur.

The CSE has not approved nor disapproved the contents of this press release, and the CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/xtm-signs-letter-of-intent-with-north-american-based-harlo-entertainment-301229779.html

SOURCE XTM Inc.

LAS VEGAS, Feb. 17, 2021 /PRNewswire/ — Allegiant (NASDAQ: ALGT) today announces two new nonstop routes connecting Key West, Fla. with Pittsburgh, Pa., and St. Petersburg-Clearwater, Fla. with Portsmouth, NH. To celebrate, Allegiant is offering one-way fares on the new routes as low as $59.*

The new routes come just a week after Allegiant announced its second largest network expansion in company history. The additions came in response to customer demand.

Also, Allegiant announced it is expanding the special limited route connecting Punta Gorda, Fla. via Punta Gorda Airport (PGD) and Rapid City, SD via Rapid City Regional Airport (RAP).

The route was originally planned to operate for two weeks in August, to coincide with the Sturgis Motorcycle Rally in South Dakota. It proved so popular, the airline quickly expanded service for the entire summer. The new route begins June 4 and will operate twice weekly.

“There is a lot of pent-up demand for travel to cities that offer a gateway to great outdoor experiences,” said Drew Wells, Allegiant’s senior vice president of revenue. “The addition of two new routes, and the expansion of the Punta Gorda–Rapid City route, reflects that demand. We expect them all to be popular, as visitors continue to seek ways to get outside.”

The new nonstop service to Key West International Airport (EYW) in Key West, Fla. from Pittsburgh, Pa. via Pittsburgh International Airport (PIT) begins June 3, 2021 with one-way fares as low as $59.* 

The nonstop service to St. Pete–Clearwater, Fla. via St. Pete-Clearwater International Airport (PIE) from Portsmouth, New Hampshire via Portsmouth International Airport (PSM) begins June 2, 2021 with one-way fares as low as $59.*

Flight days, times and the lowest fares can be found only at Allegiant.com.

*About the introductory one-way fares:

Seats and dates are limited and fares are not available on all flights. Flights must be purchased by Feb. 17, 2021 for travel by Nov. 16, 2021. Price displayed includes taxes, carrier charges & government fees. Fare rules, routes and schedules are subject to change without notice. Optional baggage charges and additional restrictions may apply. For more details, optional services and baggage fees, please visit Allegiant.com.

Allegiant – Together We Fly™

Las Vegas-based Allegiant (NASDAQ: ALGT) is an integrated travel company with an airline at its heart, focused on connecting customers with the people, places and experiences that matter most. Since 1999, Allegiant Air has linked travelers in small-to-medium cities to world-class vacation destinations with all-nonstop flights and industry-low average fares. Today, Allegiant’s all-Airbus fleet serves communities across the nation, with base airfares less than half the cost of the average domestic roundtrip ticket. For more information, visit us at Allegiant.com. Media information, including photos, is available at http://gofly.us/iiFa303wrtF

Media Contact

Phone: 702-800-2020
Email: [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/responding-to-customer-demand-allegiant-announces-service-expansion-with-new-nonstop-routes-301229598.html

SOURCE Allegiant Travel Company

LAKE SUCCESS, N.Y., Feb. 17, 2021 /PRNewswire/ — The Hain Celestial Group, Inc. (Nasdaq: HAIN) (“Hain Celestial”, “Hain” or the “Company”), a leading organic and natural products company with operations in North America, Europe, Asia and the Middle East providing consumers with A Healthier Way of Life™, today announced that the Company is hosting a fireside chat discussion at the 2021 Truist Securities Consumer Symposium on Wednesday, February 24, 2021 at 11:00 AM Eastern Time. The webcast can be accessed on Hain Celestial’s website at www.hain.com under Investor Relations and the Press & Events section.

About The Hain Celestial Group, Inc.
The Hain Celestial Group (Nasdaq: HAIN), headquartered in Lake Success, NY, is a leading organic and natural products company with operations in North America, Europe, Asia and the Middle East. Hain Celestial participates in many natural categories with well-known brands that include Celestial Seasonings®, Clarks™, Cully & Sully®, Dream®, Earth’s Best®, Ella’s Kitchen®, Farmhouse Fare™, Frank Cooper’s®, GG UniqueFiber®, Gale’s®, Garden of Eatin’®, Hain Pure Foods®, Hartley’s®, Health Valley®, Imagine®, Joya®, Lima®, Linda McCartney’s™ (under license), MaraNatha®, Natumi®, New Covent Garden Soup Co.®, Robertson’s®, Sensible Portions®, Spectrum®, Sun-Pat®, Terra®, The Greek Gods®, William’s™, Yorkshire Provender® and Yves Veggie Cuisine®. The Company’s personal care products are marketed under the Alba Botanica®, Avalon Organics®, Earth’s Best®, JASON®, Live Clean®, One Step® and Queen Helene® brands.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hain-celestial-to-participate-in-the-2021-truist-securities-consumer-symposium-301229778.html

SOURCE The Hain Celestial Group, Inc.

WATERTOWN, Mass., and Research Triangle Park, N.C., Feb. 17, 2021 /PRNewswire/ — Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced the initiation of a Phase 1 dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) containing no DNA combined with ImmTOR™. The trial aims to determine the optimal dose of ImmTOR to mitigate the formation of antibodies to AAV8 capsids used in gene therapies.

“We are pleased to further evaluate ImmTOR’s ability to reduce the formation of antibodies to AAV capsids and potentially enable gene therapy redosing by having initiated this dose-escalation study of SEL-399,” said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. “This trial builds upon our strong preclinical data in non-human primates and marks the first time that ImmTOR in conjunction with an AAV capsid has been dosed in humans, which is a significant milestone. Data from this study will inform the design of future clinical trials in patients as we seek to unlock the full potential of gene therapy.”

The dose-escalation trial of SEL-399 is designed to evaluate the safety and preliminary efficacy of ImmTOR in gene therapy. The study, being conducted in healthy volunteers at the SGS Life Sciences Clinical Pharmacology Unit in Antwerp, Belgium, plans to enroll up to 45 subjects to investigate increasing doses of ImmTOR and EMC-101. Subjects will be randomized in a 3:1 ratio of ImmTOR plus empty AAV8 capsid to empty capsid alone. Preliminary efficacy will be measured by assessing levels of AAV8-specific neutralizing antibodies.

Jude Samulski, Ph.D., chief scientific officer and co-founder of AskBio said, “By determining the dose at which ImmTOR is able to inhibit the formation of AAV-specific antibodies, this study could be a significant first step toward overcoming some of the unwanted immune responses associated with gene therapies. We look forward to using these findings to inform future studies as we work to develop strategies for repetitive dosing of AAV, thus extending durability of expression.”

Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

About AskBio
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG acquired in 2020, is a fully integrated AAV gene therapy company dedicated to developing life-saving medicines that cure genetic diseases. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, UK, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. Founded in 2001 and an early innovator in the gene therapy field, the company holds more than 500 patents in areas such as AAV production and chimeric and self-complementary capsids. Learn more at www.askbio.com or follow us on LinkedIn.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, visit www.bayer.com.

AskBio Forward-Looking Statements

This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include without limitation statements regarding AskBio’s pipeline of development candidates; AskBio’s collaboration with Selecta; AskBio’s clinical trials, including its ability to enroll subjects, the timing of any such trials and any potential side effects; whether ImmTOR will be able to reduce the formation of antibodies to AAV capsids and potentially enable gene therapy redosing; the timing of and results from the SEL-399/101 trial; whether the SEL-399/101 study could be a significant first step in overcoming the immunogenicity concerns associated with gene therapies; AskBio’s strategies for repetitive dosing of AAV, extending durability of expression; AskBio’s goal of developing life-saving medicines aimed at curing genetic diseases; and the potential benefits of AskBio’s development candidates to patients. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio’s control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans and bringing its product candidates to market, due to a variety of reasons, including the ongoing COVID-19 pandemic, possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect AskBio’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Selecta Forward-Looking Statements

Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the unique proprietary technology platform of the company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, the ability of the Company and AskBio to develop gene therapy products using ImmTOR and AskBio’s technology, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the company and AskBio to fulfill unmet medical needs, the company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the company’s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the company’s ability to grow its strategic partnerships,  and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the company’s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the company’s most recent Quarterly Report on Form 10-Q, and in other filings that the company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any intention to update any forward-looking statements included in this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/selecta-biosciences-and-askbio-initiate-first-in-human-dose-escalation-study-to-evaluate-immtor-in-gene-therapy-301229448.html

SOURCE Asklepios BioPharmaceutical, Inc.

ATLANTA, Feb. 17, 2021 /PRNewswire/ — Veritiv Corporation (NYSE:VRTV) will host a live conference call and webcast to discuss its fourth quarter and full year 2020 financial results on Wednesday, March 3, at 9 a.m. EST. To participate, callers within the U.S. and Canada can dial (833) 968-2246, and international callers can dial (825) 312-2066, both using conference ID number 7088867. Interested parties can also listen online at ir.veritivcorp.com.

A replay of the call and webcast will be available online for a limited period of time at ir.veritivcorp.com shortly after the live webcast is completed.

Prior to the March 3 financial results conference call and webcast, the Company will issue a news release and post a slide presentation online at ir.veritivcorp.com.

About Veritiv
Veritiv Corporation (NYSE: VRTV), headquartered in Atlanta and a Fortune 500^® company, is a leading North American business-to-business distributor of packaging, facility solutions, print and publishing products and services; and also a provider of logistics and supply chain management solutions. Serving customers in a wide range of industries, Veritiv has distribution centers throughout the U.S., Canada and Mexico, and team members helping shape the success of its customers.  For more information about Veritiv and its business segments visit www.veritivcorp.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/veritiv-to-release-fourth-quarter-and-full-year-2020-financial-results-on-march-3-301228934.html

SOURCE Veritiv Corporation

CAESAREA, Israel, Feb. 17, 2021 /PRNewswire/ — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced an exclusive distribution agreement with Rise General Trading, LLC for IceCure’s ProSense® Cryoablation System in the United Arab Emirates and Persian Gulf States (“the territories”).

Under the terms of the agreement, Rise General Trading, LCC will purchase a minimum amount of approximately $16 million USD of IceCure’s products over a period of three years. The first purchase order will be executed within three months after the receipt of all regulatory licenses necessary for the sale of IceCure’s products in the first territory. Licenses required by Rise General Trading, LCC include licenses for the import, marketing, and sale of IceCure’s products to the relevant territory. The product distribution will be overseen by the Rise Healthcare division, which manages a diversified portfolio of medical devices for Oncology, Pediatrics and Respiratory specialties.

“We are delighted to forge this new strategic partnership with Rise General Trading, LCC who can distribute our highly innovative tumor cryoablation therapy across several new international markets,” said Eyal Shamir, Chief Executive Officer of IceCure. “This enables IceCure to significantly expand into several new, high growth opportunities in the United Arab Emirates and Persian Gulf States. This agreement follows the successful exclusive distribution agreement with Terumo to accelerate the commercialization of our cryoablation technology in Japan, Thailand, and Singapore. These partnerships are pivotal to IceCure’s strategic initiatives and reflect the continued momentum of the Company’s global expansion into fast-growing markets, allowing more cancer patients access to the ProSense® Cryoablation System.” 

“Through our partnership with IceCure Medical, we are uniquely positioned to bring the ProSense® Cryoablation System to the GCC region, providing a true value to cancer patients seeking minimally invasive alternatives to surgery. ProSense’s cutting-edge liquid nitrogen (LN2) technology fits in perfectly with Rise’s mission to bring the most advanced oncology treatments to the people of our region,” said Felix Moral, CEO of Rise General Trading, LCC. 

About IceCure Medical

Founded in 2006, Israel-based IceCure Medical (TASE: ICCM), develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals. To learn more, please visit: www.icecure-medical.com.

About Rise General Trading, LCC

Rise General Trading, LCC is a technology group founded in 2009 and belonging to National Holding, one of the largest private conglomerates in UAE and the GCC, with strategic investments across diversified sectors of the economy. Rise General Trading, LCC is owned and managed portfolio covers food technologies, medical devices, smart retail, augmented reality and artificial intelligence technologies for oil & gas industries, and security and cybersecurity solutions both for government and private sectors. Rise International is developing partnerships and joint ventures with more leading multinational companies, in order to strengthen its business throughout the entire trade chain, with production, distribution, retail and international franchise operations.

Forward Looking Statements

The foregoing about completing the Transaction is Forward-Looking Information, as defined in the Securities Law, which depends on factors outside the Company’s control, including the General Meeting’s approval of the Transaction and receiving TASE’s approval to list the securities for trading. In addition, the statements about listing the Company shares for trading on NASDAQ without the need for a concurrent public offering depend on factors that are outside the Company’s control, including the Company meeting NASDAQ rules and provisions at the time of listing, market conditions, receiving the SEC’s approval for the listing document and the document’s entry into effect. In view of the foregoing, this information might not materialize or materialize significantly differently than described above.

Communication Contact:
Tlalit Bussi Tel Tzure
VP BD & Marketing
IceCure Medical Ltd
T: +972.54.565.0737
[email protected]

IR Contact:

Jeremy Feffer

T: 212.915.2568 | M: 917.749.1494
[email protected]

 

 

 

View original content:http://www.prnewswire.com/news-releases/icecure-signs-exclusive-distribution-agreement-with-rise-general-trading-lcc-expanding-market-reach-across-the-middle-east-301229912.html

SOURCE IceCure Medical

HONG KONG, Feb.17, 2021 /PRNewswire/ — CLPS Incorporation (Nasdaq: CLPS) (“CLPS” or “the Company”), today announced that, through its wholly-owned subsidiary, CLPS Technology (California) Inc. (“CLPS California”), it has signed a vendor agreement (the “Agreement”) with a well-known U.S. digital payment platform (the “Client”) to provide IT services, including data analysis and payment risk management for their international business.

Growing beyond the Mainland China market, CLPS has been extending its presence and client base internationally, including blue chip financial institutions to meet the strong demand for IT services. The Company’s competitive advantage and expertise in the payment industry are contributing factors that made the contract with the Client headquartered in the U.S. possible. It enables the well-established business relationship of both parties to transpire in the international market.

Mr. Matthew Tang, Chief Executive Officer of CLPS US & HK, said, “We are extremely honored that for more than six years of cooperation, the Client has awarded us with a global contract. This also aligns with our global strategy by leveraging our expertise in the financial industry with globally competitive IT services to achieve and exceed exceptional client satisfaction.”

Mr. Henry Li, Chief Operating Officer of CLPS, said, “The pace of change across the payment industry has significantly accelerated in the span of the COVID-19 pandemic, which reshaped the people’s lives across the world. It has always been our commitment to deliver comprehensive IT services to the Client ensuring a safe and secured online payment transactions. In addition, the new contract we gained is another step forward in our U.S. footprint.”

About CLPS Incorporation

Headquartered in Hong Kong, CLPS Incorporation (the “Company”) (Nasdaq: CLPS) is a global leading information technology (“IT”), consulting and solutions service provider focusing on the banking, insurance and financial sectors. The Company serves as an IT solutions provider to a growing network of clients in the global financial industry, including large financial institutions in the US, Europe, Australia, Southeast Asia and Hong Kong, and their PRC-based IT centers. The Company maintains 19 delivery and/or research & development centers to serve different customers in various geographic locations. Mainland China centers are located in Shanghai, Beijing, Dalian, Tianjin, Baoding, Chengdu, Guangzhou, Shenzhen, Hangzhou, Suzhou, and Hainan. The remaining eight global centers are located in Hong Kong SAR, USA, UK, Japan, Singapore, Malaysia, Australia, and India. For further information regarding the Company, please visit: http://ir.clpsglobal.com/, or follow CLPS on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to the Company’s beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the Company’s control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All such statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties related to the Company’s financial and operational performance in the second half and full year of fiscal 2020, its expectations of the Company’s future performance, its preliminary outlook and guidance offered in this presentation, as well as the risks and uncertainties described in the Company’s most recently filed SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact: 

CLPS Incorporation
Rhon Galicha
Investor Relations Office 
Phone: +86-182-2192-5378
Email: [email protected]

View original content:http://www.prnewswire.com/news-releases/clps-incorporation-signs-vendor-agreement-with-a-well-known-us-digital-payment-platform-ramps-up-global-expansion-strategy-301229797.html

SOURCE CLPS